inXso 2021 MedTech Series – R&D focal points

Expos, trade fairs, and shows are a way to build business networks and search for partners that open new potential markets. It brings a lot of positive exposure for companies and their innovations, builds customer interest, and opens doors for collaborative projects along the life science and medical technology value chain.

The EU Research and Innovation Programme 2021-2027 has gathered a lot of attention from the research communities around Europe this time around with their Cluster Health topics that are open for proposals. The published destinations aim to address acute and long-term problems in the healthcare ecosystem and the health and well-being of citizens from a societal point of view – without forgetting the lessons learned from the Covid-19 pandemic.

For 2021 inXso has created a webinar series outlining some specific features that are essential for global design of medical technology, and introduces some regulatory aspects in context of EU MDR and Swiss regulatory landscape, as well as some basic features from Chinese and Japanese regulations that everyone – or every company – considering these healthcare markets should now of.

It is a known fact that most internationalization attempts fail due to lack of thorough preparation and adhering to the chosen strategy.

When it comes to life sciences – healthcare technology, biomedical technology and pharmaceuticals – that is an industry operating in a heavily regulated environment, any attempt to seek market growth through internationalization faces a multitude of specific considerations.

In recent years medical technology has taken a trend towards creating personalized care while seeking ways to enhance quality for patients and to lower healthcare costs. At the same time developers have to keep in mind the ease of use of the devices and gaining regulatory approval for them in the highly internationalized market.

The life science industry distinguishes itself from other high-technology industries with such fundamental dimensions as applying scientific knowledge to provide technological solutions aiming to improve health care and quality of life – in a highly regulated environment. At the same time, usually purchasing decisions are not made by end-consumers, but their physicians or such third party as an insurance company, for example.

On 22nd May an online pitching for HealthTech Startups is organized by inXso together with Slush China to Venture Capital investors of which there is a significant participation from the Chinese Venture Capital investment companies focused on HealthTech, BioPharma and BioMedTech.

In our series focusing on Health Tech in Chinese market inXso is organizing an interactive webinar “Health Tech China Focus” together with Tampere HealthHUB that will briefly discuss some of the key points and rather unique aspects of Chinese Health Tech initiatives and their implementation.